Epidemiology and clinical aspects on hepatitis C

Area of Science:

• Hepatology
• Virology
• Oncology

Background:

• Hepatitis C virus (HCV) affects 170 million globally, causing chronic liver disease and increasing hepatocellular carcinoma (HCC) risk.
• HCV infection often leads to chronic hepatitis, with spontaneous clearance being rare and progression to advanced liver disease and HCC common over decades.
• Extrahepatic manifestations, such as cryoglobulinemia, are frequently associated with chronic HCV liver disease.

Purpose of the Study:

• To review the impact of Hepatitis C virus (HCV) on liver disease and cancer.
• To evaluate the efficacy of different antiviral treatment strategies for chronic hepatitis C.
• To discuss the implications of treatment on reducing HCC occurrence.

Main Methods:

• Literature review of HCV epidemiology, pathogenesis, and treatment outcomes.
• Analysis of sustained virologic response (SVR) rates for various interferon-based therapies.
• Examination of the relationship between antiviral treatment and HCC incidence.

Main Results:

• HCV infection is a leading cause of chronic liver disease and HCC globally.
• HCV genotype 1b and high viral load are associated with lower SVR rates with older interferon monotherapy.
• Combination therapy with interferon and ribavirin, and more recently pegylated interferon, have significantly increased SVR rates.

Conclusions:

• Antiviral treatments for HCV, particularly pegylated interferon, are effective in achieving high SVR rates.
• Effective antiviral therapy is crucial for reducing the incidence of HCV-related HCC.
• Development of an effective HCV vaccine remains a critical unmet need despite extensive research efforts.